For the Inventor, By the Inventor

Enter assignee name

Research Triangle Park, NC, United States of America

Athenix Corporation

USPTO Granted Patents = 86

% Expired Patents = 33.7

CIPO Patents = 19

EPO Patents = 34

Forward Citations = 454

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Nicholas B Duck (34 out of 57 patents)

Kimberly S Sampson (30 out of 39 patents)

Daniel John Tomso (29 out of 34 patents)

4. Nadine B Carozzi (24 out of 31 patents)

5. Michael G Koziel (23 out of 71 patents)

6. Tracy Hargiss (21 out of 21 patents)

7. Brian S Carr (20 out of 81 patents)

8. Brian Vande Berg (15 out of 19 patents)

9. Volker Heinrichs (14 out of 17 patents)

10. Philip E Hammer (14 out of 37 patents)

11. Laura Cooper Schouten (12 out of 15 patents)

12. Cheryl Peters (11 out of 17 patents)

13. Duane Alan Lehtinen (10 out of 22 patents)

14. Todd K Hinson (9 out of 9 patents)

15. Nalini M Desai (9 out of 37 patents)

Core Competencies:

Delta-Endotoxin

Pesticidal Genes

EPSP Synthase

Insecticidal Proteins

Herbicide Resistance

Nematode Toxins

Gene Design

Biotechnology

Transgenic Plants

Genetic Diversity

Synthetic Genes

Variant Proteins

86 patents: Sort by Forward Citations

1. 10221431 - AXMI422 toxin gene and methods for its use (2019-03-05),

2. 10059960 - AXMI221z, AXMI222z, AXMI223z, AXMI224z, and AXMI225z delta-endotoxin genes and methods for their use (2018-08-28),

3. 9982274 - AXMI115 variant insecticidal gene and methods for its use (2018-05-29),

4. 9909140 - AXMI-115, AXMI-113, AXMI-005, AXMI-163 and AXMI-184: insecticidal proteins and methods for their use (2018-03-06),

5. 9862967 - AXMI281 toxin gene and methods for its use (2018-01-09),

6. 9862965 - AXMI205 variant proteins and methods of use (2018-01-09),

7. 9790258 - AXMI335 toxin gene and methods for its use (2017-10-17),

8. 9758793 - AXMI-234 and AXMI-235 delta-endotoxin genes and methods for their use (2017-09-12),

9. 9752158 - AXMI115 variant insecticidal gene and methods for its use (2017-09-05),

10. 9725735 - AXMI345 delta-endotoxin gene and methods for its use (2017-08-08),

11. 9695440 - AXMI232, AXMI233, and AXMI249 toxin genes and methods for their use (2017-07-04),

12. 9556255 - Toxin genes and methods for their use (2017-01-31),

13. 9528122 - Axmi270 toxin gene and methods of use (2016-12-27),

14. 9321814 - AXMI238 toxin gene and methods for its use (2016-04-26),

15. 9260487 - AXMI-205 pesticidal gene and method for its use (2016-02-16),

Athenix Corporation is a biotechnology company focused on developing novel therapies to address unmet medical needs in the field of regenerative medicine. With a vision to transform the lives of patients through innovation, Athenix leverages cutting-edge technologies to advance the understanding and application of cell-based therapies. The company's mission is to pioneer breakthrough treatments that restore and enhance the body's natural healing processes. Through strategic collaborations and a dedicated interdisciplinary team, Athenix aims to make a meaningful impact on global healthcare.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Athenix Corporation

86 Patents

#9 in Research Triangle Park, NC

#109 in North Carolina

#4,331 in US

#8,853 in the World

Research Triangle Park, NC, United States of America

Athenix Corporation

Forward Citations = 454

34 inventors:

Nicholas B Duck (34 out of 57 patents)

Kimberly S Sampson (30 out of 39 patents)

Daniel John Tomso (29 out of 34 patents)

4. Nadine B Carozzi (24 out of 31 patents)

5. Michael G Koziel (23 out of 71 patents)

Please report any incorrect information to [email protected]

Loading…